Abstract
Objectives: We assessed SARS-CoV-2 infection, seroprevalence and seroconversion in students and staff when secondary schools reopened in March 2021.
Methods: We initiated SARS-CoV-2 surveillance in 18 secondary schools across six regions in September 2020. Participants provided nasal swabs for RT-PCR and blood samples for SARS-CoV-2 antibodies at the beginning (September 2020) and end (December 2020) of the autumn term and at the start of the spring term (March 2021).
Findings: In March 2021, 1895 participants (1100 students:795 staff) were tested; 5.6% (61/1094) students and 4.4% (35/792) staff had laboratory-confirmed SARS-CoV-2 infection from December 2020-March 2021. Nucleoprotein-antibody seroprevalence was 36.3% (370/1018) in students and 31.9% (245/769) in staff, while spike-antibody prevalence was 39.5% (402/1018) and 59.8% (459/769), respectively, similar to regional community seroprevalence. Between December 2020 and March 2021, 14.8% (97/656; 95%CI: 12.2–17.7) students and 10.0% (59/590; 95%CI: 7.7–12.7) staff seroconverted. Weekly seroconversion rates were similar from September to December 2020 (8.0/1000) and from December 2020 to March 2021 (7.9/1000; students: 9.3/1,000; staff: 6.3/1,000).
Interpretation: By March 2021, a third of secondary school students and staff had evidence of prior infection based on N-antibody seropositivity, and an additional third of staff had evidence of vaccine-induced immunity based on S-antibody seropositivity.
Original language | English |
---|---|
Pages (from-to) | 573-580 |
Number of pages | 8 |
Journal | Journal of Infection |
Volume | 83 |
Issue number | 5 |
Early online date | 13 Aug 2021 |
DOIs | |
Publication status | Published - Nov 2021 |
Bibliographical note
Funding Information: This surveillance was funded by the Department of Health and Social Care (DHSC).MR reports that The Immunization and Countermeasures Di- vision has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. RB and EL reports other from GSK, other from Sanofi, other from Pfizer, outside the submitted work. MK reports grants from Gilead Sciences Inc, out- side the submitted work. Dr. Garstang reports grants from Public Health England, during the conduct of the study. All other authors have nothing to declare.
Open Access: Free to read, but no Open Access licence.
Publisher Copyright: ©2021 Published by Elsevier Ltd on behalf of The British Infection Association.
Citation: Ladhani, Shamez N., et al. "Emergence of SARS-CoV-2 Alpha (B. 1.1. 7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: active prospective surveillance, December 2020 to March 2021, England." Journal of Infection 83.5 (2021): 573-580.
DOI: https://doi.org/10.1016/j.jinf.2021.08.019
Keywords
- COVID-19
- CHILDREN
- TIME